Gene Editing

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Posted on February 21, 2023 by Editorial Staff

-Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S. rolling Biologics Licensing Application (BLA) submission on track for completion by end of Q1 2023- -Enrollment and dosing ongoing

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='facebook' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/facebook.svg'>

Share on Facebook

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='Twitter' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/Twitter.svg'>

<img style='max-height: 25px;display:unset;margin:0' class='sfsi_wicon' alt='Follow' src='https://thecrisprsociety.com/wp-content/plugins/ultimate-social-media-icons/images/responsive-icon/Follow.png'>

<img alt='' src='https://secure.gravatar.com/avatar/008c46a8d463cb955213048824ccf788?s=90&d=identicon&r=g' srcset='https://secure.gravatar.com/avatar/008c46a8d463cb955213048824ccf788?s=180&d=identicon&r=g 2x' class='avatar avatar-90 photo' height='90' width='90' decoding='async'/>

Editorial Staff